{"id":200614,"date":"2026-08-13T10:57:35","date_gmt":"2026-08-13T05:27:35","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=200614"},"modified":"2026-08-13T10:57:37","modified_gmt":"2026-08-13T05:27:37","slug":"dr-lal-pathlabs-vs-metropolis-healthcare","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare\/","title":{"rendered":"Dr Lal PathLabs vs Metropolis Healthcare: Share Price, PE and ROE Compared"},"content":{"rendered":"
<\/div>\n

Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59.90x, ROE 20.13%, Div 1.05%. Metropolis Healthcare MCap Rs 11,453 Cr, PE 56.47x, ROE 12.56%.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Dr Lal PathLabs and Metropolis Healthcare are both listed diagnostics chains. Dr Lal at Rs 32,723 Cr is about 3 times larger with a higher ROE of 20.13% at PE 59.90x. Metropolis at Rs 11,453 Cr trades at PE 56.47x with ROE 12.56%. Both pay modest dividends. Dr Lal’s North India leadership versus Metropolis’s South and West India focus shapes their geographic strategies.<\/p>\n<\/div>\n

The Dr Lal PathLabs vs Metropolis Healthcare question comes up often among investors who follow the Diagnostics and pathology space in India. Dr Lal PathLabs MCap Rs 32,723 Cr, PE 59. 90x, ROE 20. This article goes through what each company does, their latest financial performance, and the key numbers that matter for anyone evaluating Dr Lal PathLabs vs Metropolis Healthcare as a research exercise.<\/p>\n

All data cited here is sourced from publicly available company filings. Verify the latest prices and fundamentals on NSE or BSE before acting on any information.<\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n